David Dunger

Prof. David Dunger

University of Cambridge

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2000 in BMJ
Verified
Journal Article
Closed access
PDF file
KOKen K L Ong
Ken K L Ong
MAMarion L Ahmed
Marion L Ahmed
PEPauline Marion Emmett
Pauline Marion Emmett
MPMichael A Preece
Michael A Preece
DDDavid Dunger
David Dunger
Objective: To identify predictors of postnatal catch-up growth from birth to two years and its relation to size and obesity at five years. Design: Regional prospective cohort study. Setting: Avon longitudinal study of pregnancy and childhood, United Kingdom. Subjects: 848 full term singletons from a 10% random sample of the Avon longitudinal study of pregnancy and childhood. Main outcome measures: Maternal birth weight, prepregnancy weight, pregnancy weight gain, height, smoking, and parity, and paternal height. Weight and length of infants at birth, two years, and five years expressed as standard deviation (SD) scores from the UK reference scores for 1990. Percentage fat mass and total fat mass (estimated from skinfolds) and waist circumference at five years. Results: Size at birth was representative of the national reference. Overall, 30.7% (260 of 848) of infants showed a gain in SD score for weight greater than 0.67 SD scores between zero and two years, indicating clinically significant catch-up growth. These children had lower weight, length, and ponderal index at birth than other children, and were more often from primiparous pregnancies. They also had taller fathers than other children, and their mothers had lower birth weights and were more likely to smoke during pregnancy. Children who showed catch-up growth between zero and two years were heavier, taller, and fatter (body mass index, percentage body fat, and waist circumference) at five years than other children. Conclusions: In this contemporary well nourished cohort, catch-up growth was predicted by factors relating to intrauterine restraint of fetal growth. Children who showed catch-up growth between zero and two years were fatter and had more central fat distribution at five years than other children. Mechanisms that signal and regulate early catch-up growth in the postnatal period may influence associations between small size at birth and risks for disease in adulthood.

6 June 2007 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JTJohn A Todd
John A Todd
NWNeil M Walker
Neil M Walker
JCJason D Cooper
Jason D Cooper
DSDeborah J Smyth
Deborah J Smyth
KDKate Downes
Kate Downes
DCDavid G Clayton
David G Clayton

1 July 2007 in Diabetes Care
Verified
Journal Article
Open access
PDF file
BMBoyd E. Metzger
Boyd E. Metzger
TBThomas A. Buchanan
Thomas A. Buchanan
DCDonald R. Coustan
Donald R. Coustan
ALAlberto de Leiva
Alberto de Leiva
DDDavid Dunger
David Dunger
CZChristos Zoupas
Christos Zoupas

14 May 2006 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DSDeborah J Smyth
Deborah J Smyth
JCJason D Cooper
Jason D Cooper
RBRebecca Bailey
Rebecca Bailey
SFSarah Field
Sarah Field
OBOliver Burren
Oliver Burren
JTJohn A Todd
John A Todd

28 May 2004 in Science
Verified
Journal Article
Closed access
PDF file
SGStella George
Stella George
Justin J. RochfordJustin J. Rochford
Justin J. Rochford
CWChristian Wolfrum
Christian Wolfrum
SGSarah L. Gray
Sarah L. Gray
SSSven Schinner
Sven Schinner
IBInês Barroso
Inês Barroso
Inherited defects in signaling pathways downstream of the insulin receptor have long been suggested to contribute to human type 2 diabetes mellitus. Here we describe a mutation in the gene encoding the protein kinase AKT2/PKBβ in a family that shows autosomal dominant inheritance of severe insulin resistance and diabetes mellitus. Expression of the mutant kinase in cultured cells disrupted insulin signaling to metabolic end points and inhibited the function of coexpressed, wild-type AKT. These findings demonstrate the central importance of AKT signaling to insulin sensitivity in humans.

1 December 2016 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
RBRebecca J. Brown
Rebecca J. Brown
DADavid Araujo-Vilar
David Araujo-Vilar
PCPik To Cheung
Pik To Cheung
DDDavid Dunger
David Dunger
AGAbhimanyu Garg
Abhimanyu Garg
TYTohru Yorifuji
Tohru Yorifuji
Objective: Lipodystrophy syndromes are extremely rare disorders of deficient body fat associated with potentially serious metabolic complications, including diabetes, hypertriglyceridemia, and steatohepatitis. Due to their rarity, most clinicians are not familiar with their diagnosis and management. This practice guideline summarizes the diagnosis and management of lipodystrophy syndromes not associated with HIV or injectable drugs. Participants: Seventeen participants were nominated by worldwide endocrine societies or selected by the committee as content experts. Funding was via an unrestricted educational grant from Astra Zeneca to the Pediatric Endocrine Society. Meetings were not open to the general public. Evidence: A literature review was conducted by the committee. Recommendations of the committee were graded using the system of the American Heart Association. Expert opinion was used when published data were unavailable or scarce. Consensus Process: The guideline was drafted by committee members and reviewed, revised, and approved by the entire committee during group meetings. Contributing societies reviewed the document and provided approval. Conclusions: Lipodystrophy syndromes are heterogeneous and are diagnosed by clinical phenotype, supplemented by genetic testing in certain forms. Patients with most lipodystrophy syndromes should be screened for diabetes, dyslipidemia, and liver, kidney, and heart disease annually. Diet is essential for the management of metabolic complications of lipodystrophy. Metreleptin therapy is effective for metabolic complications in hypoleptinemic patients with generalized lipodystrophy and selected patients with partial lipodystrophy. Other treatments not specific for lipodystrophy may be helpful as well (eg, metformin for diabetes, and statins or fibrates for hyperlipidemia). Oral estrogens are contraindicated.